FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042491566> ?p ?o ?g. }

• W2042491566 endingPage "419" @default.
• W2042491566 startingPage "414" @default.
• W2042491566 abstract "The objective of this study was to investigate the efficacy and safety of bromocriptine (BRC) as an adjunct to conventional treatment in systemic lupus erythematosus (SLE). A prospective, doubleblind, randomized, placebo-controlled study compared BRC at a fixed daily dosage of 2.5 mg with placebo. Patients were followed for 2–17 months (mean 12.5 months). Disease activity was assessed using the SLE Disease Activity Index (SLEDAI), numbers of flares were recorded, and serum prolactin (PRL) levels were obtained at intervals during the study. Patients were allowed to take prednisone and immunosuppressive drugs. Sixty-six patients with SLE entered the study. Thirty-six were treated with BRC, and 30 controls received placebo. Sixteen patients were removed from the study during the treatment period: five in each group left the study because of adverse effects, five became pregnant, and one patient who took placebo died with central nervous system lupus. Four patients in the BRC treatment group and three patients in the placebo group moved away or stopped coming for study visits for unknown reasons, and were lost to follow-up during the course. At entry, serum PRL was (mean–s.d.) 24.8 ng/ml–18.4 in the BRC treatment group. This value fell to 5.8–9.0 after 12 months of treatment. Corresponding PRL values in controls were 23.7–22.1 pretreatment and 20.3–14 after 12 months. PRL levels in BRC-treated subjects were significantly lower than levels in control subjects after 3, 6, 9, and 12 months of treatment. The SLEDAI score on the fifth protocol visit was decreased significantly in the BRC group vs controls: 0.9–1.4 vs 2.6–4.5 (P < 0.05). Although the absolute number of flares in each group was similar, the mean number of flares/patient/month was decreased significantly in the BRC group compared to the control group (0.08–0.1 vs 0.18–0.2, P = 0.03). Long term treatment with a low dose of BRC appears to be a safe and effective means of decreasing SLE flares in SLE patients." @default.
• W2042491566 created "2016-06-24" @default.
• W2042491566 creator A5002661998 @default.
• W2042491566 creator A5013843439 @default.
• W2042491566 creator A5018949209 @default.
• W2042491566 creator A5028164254 @default.
• W2042491566 creator A5054369864 @default.
• W2042491566 creator A5091177403 @default.
• W2042491566 date "1998-07-01" @default.
• W2042491566 modified "2023-10-01" @default.
• W2042491566 title "Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study" @default.
• W2042491566 cites W1973418999 @default.
• W2042491566 cites W1981878221 @default.
• W2042491566 cites W1986399620 @default.
• W2042491566 cites W1998086688 @default.
• W2042491566 cites W2004421882 @default.
• W2042491566 cites W2007011638 @default.
• W2042491566 cites W2009347155 @default.
• W2042491566 cites W2012704907 @default.
• W2042491566 cites W2017854040 @default.
• W2042491566 cites W2019142067 @default.
• W2042491566 cites W2035942340 @default.
• W2042491566 cites W2046489645 @default.
• W2042491566 cites W2062320562 @default.
• W2042491566 cites W2064999867 @default.
• W2042491566 cites W2070894640 @default.
• W2042491566 cites W2094588784 @default.
• W2042491566 cites W2107062893 @default.
• W2042491566 cites W2111160399 @default.
• W2042491566 cites W2146203649 @default.
• W2042491566 doi "https://doi.org/10.1191/096120398678920334" @default.
• W2042491566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9736326" @default.
• W2042491566 hasPublicationYear "1998" @default.
• W2042491566 type Work @default.
• W2042491566 sameAs 2042491566 @default.
• W2042491566 citedByCount "110" @default.
• W2042491566 countsByYear W20424915662012 @default.
• W2042491566 countsByYear W20424915662013 @default.
• W2042491566 countsByYear W20424915662014 @default.
• W2042491566 countsByYear W20424915662015 @default.
• W2042491566 countsByYear W20424915662016 @default.
• W2042491566 countsByYear W20424915662017 @default.
• W2042491566 countsByYear W20424915662019 @default.
• W2042491566 countsByYear W20424915662020 @default.
• W2042491566 countsByYear W20424915662021 @default.
• W2042491566 countsByYear W20424915662022 @default.
• W2042491566 countsByYear W20424915662023 @default.
• W2042491566 crossrefType "journal-article" @default.
• W2042491566 hasAuthorship W2042491566A5002661998 @default.
• W2042491566 hasAuthorship W2042491566A5013843439 @default.
• W2042491566 hasAuthorship W2042491566A5018949209 @default.
• W2042491566 hasAuthorship W2042491566A5028164254 @default.
• W2042491566 hasAuthorship W2042491566A5054369864 @default.
• W2042491566 hasAuthorship W2042491566A5091177403 @default.
• W2042491566 hasConcept C126322002 @default.
• W2042491566 hasConcept C142724271 @default.
• W2042491566 hasConcept C159654299 @default.
• W2042491566 hasConcept C168563851 @default.
• W2042491566 hasConcept C197934379 @default.
• W2042491566 hasConcept C203014093 @default.
• W2042491566 hasConcept C204787440 @default.
• W2042491566 hasConcept C27081682 @default.
• W2042491566 hasConcept C2775915377 @default.
• W2042491566 hasConcept C2776856834 @default.
• W2042491566 hasConcept C2776912625 @default.
• W2042491566 hasConcept C2778720950 @default.
• W2042491566 hasConcept C2779064019 @default.
• W2042491566 hasConcept C2779134260 @default.
• W2042491566 hasConcept C71315377 @default.
• W2042491566 hasConcept C71924100 @default.
• W2042491566 hasConcept C90924648 @default.
• W2042491566 hasConceptScore W2042491566C126322002 @default.
• W2042491566 hasConceptScore W2042491566C142724271 @default.
• W2042491566 hasConceptScore W2042491566C159654299 @default.
• W2042491566 hasConceptScore W2042491566C168563851 @default.
• W2042491566 hasConceptScore W2042491566C197934379 @default.
• W2042491566 hasConceptScore W2042491566C203014093 @default.
• W2042491566 hasConceptScore W2042491566C204787440 @default.
• W2042491566 hasConceptScore W2042491566C27081682 @default.
• W2042491566 hasConceptScore W2042491566C2775915377 @default.
• W2042491566 hasConceptScore W2042491566C2776856834 @default.
• W2042491566 hasConceptScore W2042491566C2776912625 @default.
• W2042491566 hasConceptScore W2042491566C2778720950 @default.
• W2042491566 hasConceptScore W2042491566C2779064019 @default.
• W2042491566 hasConceptScore W2042491566C2779134260 @default.
• W2042491566 hasConceptScore W2042491566C71315377 @default.
• W2042491566 hasConceptScore W2042491566C71924100 @default.
• W2042491566 hasConceptScore W2042491566C90924648 @default.
• W2042491566 hasIssue "6" @default.
• W2042491566 hasLocation W20424915661 @default.
• W2042491566 hasLocation W20424915662 @default.
• W2042491566 hasOpenAccess W2042491566 @default.
• W2042491566 hasPrimaryLocation W20424915661 @default.
• W2042491566 hasRelatedWork W1980179952 @default.
• W2042491566 hasRelatedWork W2024887137 @default.
• W2042491566 hasRelatedWork W2027099120 @default.
• W2042491566 hasRelatedWork W2030144383 @default.
• W2042491566 hasRelatedWork W2035004278 @default.

• next